Nuclear Medicine and Biology
Volume 36, Issue 2 , Pages 117-128 , February 2009

Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with 177Lu: in vitro comparison of acyclic and macrocyclic ligands

Received 9 October 2008 ,Revised 29 October 2008 ,Accepted 1 November 2008.

References 

  1. Garcia de Palazzo IE, Adams GP, Sundareshan P, Wong AJ, Testa JR, Bigner DD, et al. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res. 1993;53:3217–3220
  2. Schwechheimer K, Huang S, Cavenee WK. EGFR Gene amplification-rearrangement in human glioblastomas. Int J Cancer. 1995;62:145–148
  3. Antonyak MA, Moscatello DK, Wong AJ. Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J Biol Chem. 1998;273:2817–2822
  4. Moscatello DK, Holgado-Madruga M, Emlet DR, et al. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem. 1998;273:200–206
  5. Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J NeuroVirol. 1998;4:148–158
  6. O'Donoghue JA, Bsrdies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med. 1995;36:1902–1909
  7. Reardon DA, Zalutsky MR, Bigner DD. Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev Anti-Cancer Therapy. 2007;7:675–687
  8. DeNardo GL, DeNardo SJ, Miyao NP. Non-dehalogenation mechanisms for excretion of radioiodine after administration of labeled antibodies. Int J Biol Markers. 1988;3:1–9
  9. Hanna R, Ong GL, Mattes MJ. Processing of antibodies bound to B-cell lymphomas and other hematological malignancies. Cancer Res. 1996;56:3062–3068
  10. Heeg MJ, Jurisson SS. The role of inorganic chemistry in the development of radiometal agents for cancer therapy. Acc Chem Res. 1999;32:1053–1060
  11. Press OW, Shan D, Howell-Clark J, Eary J, Appelbaum FR, Matthews D, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 1996;56:2123–2129
  12. Shih LB, Thorpe SR, Griffiths GL, Diril H, Ong GL, Hansen HJ, et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med. 1994;35:899–908
  13. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453–2463
  14. Volkert WA, Goeckler WF, Ehrhardt GJ, Ketring AR. Therapeutic radionuclides: Production and decay property considerations. J Nucl Med. 1991;32:174–185
  15. Ahlgren S, Orlova A, Rosik D, Sandström M, Sjöberg A, Baastrup B, et al. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. Bioconjugate Chem. 2008;19:235–243
  16. Banerjee S, Das T, Chakraborty S, Samuel G, Korde A, Srivastava S. 177Lu-DOTA-lanreotide: a novel tracer as a targeted agent for tumor therapy. Nucl Med Biol. 2004;31:753–759
  17. Parry JJ, Kelly TS, Andrews R, Rogers BE. In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin (7–14) analogues containing different amino acid linker moieties. Bioconjugate Chem. 2007;18:1110–1117
  18. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000;60:5237–5243
  19. Bousquet JC, Saini S, Stark DD, Hahn PF, Nigam M, Wittenberg J, et al. Gd-DOTA: characterization of a new paramagnetic complex. Radiology. 1988;166:693–698
  20. McMurry TJ, Brechbiel M, Kumar K, Gansow OA. Convenient synthesis of bifunctional tetraaza macrocycles. Bioconjugate Chem. 1992;3:108–117
  21. Moi MK, Meares CF, DeNardo SJ. The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid and study of its yttrium(III) complex. Journal of the American Chemical Society. 1988;110:6266–6267
  22. Parker D. Tumour targeting with radiolabelled macrocycle–antibody conjugates. Chem Soc Rev. 1990;19:271–291
  23. Woods M, Kovacs Z, Kiraly R, Brucher E, Zhang S, Sherry AD. Solution dynamics and stability of lanthanide(III) (S)-2-(p-nitrobenzyl)-DOTA complexes. Inorg Chem. 2004;2845–2851
  24. Durbin P. Metabolic characteristics within a chemical family. Health Phys. 1960;2:225–228
  25. Brouwers AH, van Eerd JEM, Frielink C, Oosterwijk E, Oyen WJG, Corstens FHM, et al. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med. 2003;45:327–337
  26. Clauhan SC, Jain M, Moore ED, Wittel UA, Li J, Gwilt PW, et al. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49. Eur J Nucl Med Mol Imaging. 2005;32:264–273
  27. Grunberg J, Novak-Hofer I, Honer M, Zimmermann K, Knogler K, Blauenstein P, et al. In vivo evaluation of 177Lu-and 67/64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumors. Clin Cancer Res. 2005;11:5112–5120
  28. Postema EJ, Frielink C, Oyeen WJ, Raemakers JM, Goldenberg DM, Corstens FH, et al. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (epratuzumab) in nude mice with CD22-positive lymphoma. Cancer Biother Radiopharm. 2003;18:525–533
  29. Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, et al. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med. 2006;47:1127–1135
  30. Yordanov AT, Hens M, Pegram CN, Bigner DD, Zalutsky MR. Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. Nuclear Medicine and Biology. 2007;34:173–183
  31. Vaidyanathan G, Affleck D, Li J, Welsh P, Zalutsky MR. A polar substituent-containing acylation agent for the radioiodination of internalizing monoclonal antibodies: N-succinimidyl 4-guanidinomethyl-3-[131I]iodobenzoate ([131I]SGMIB). Bioconjugate Chem. 2001;12:428–438
  32. Humphrey PA, Wong AJ, Vogelstein B, Zalutsky MR, Fuller GN, Archer GE, et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Nat Acad Sci U S A. 1990;87:4207–4211
  33. Wikstrand CJ, Hale LP, Batra SK, Hill L, Humphrey PA, Kurpad SK, et al. Monoclonal antibodies against EGFRvllI are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 1995;55:3140–3148
  34. Stetter H, Frank W. Complex formation with tetraazacycloalkane-N,N′,N″,N′″-tetraacetic acids as a function of ring size. Angewandte Chemie. 1976;88:760
  35. Pippin CG, Parker T, McMurry TJ, Brechbiel MW. Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjugate Chemistry. 1992;3:342–344
  36. Milenic DE, Garmestani K, Chappell LL, Dadachova E, Yordanov A, Ma D, et al. In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. Nucl Med Biol. 2002;29:431–442
  37. Foulon CF, Reist CJ, Bigner DD, Zalutsky MR. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody. Cancer Res. 2000;60:4453–4460
  38. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77–89
  39. Reist CJ, Archer GE, Kurpad SN, Wikstrand CJ, Vaidyanathan G, Willingham MC, et al. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res. 1995;55:4375–4382
  40. Enam SA, Rosenblum ML, Edvardsen K. Role of extracellular matrix in tumor invasion: migration of glioma cells along fibronectin-positive mesenchymal cell processes. Neurosurgery. 1998;42:599–607
  41. Shankar S, Vaidyanathan G, Affleck DJ, Welsh P, Zalutsky MR. N-Succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate, a negatively charged substituent-bearing acylation agent for the radioiodination of peptides and mAbs. Bioconjugate Chem. 2003;14:331–341
  42. Vaidyanathan G, Alston KL, Bigner DD, Zalutsky MR. Nɛ-(3-[⁎I]iodobenzoyl)-Lys5-Nαmaleimido-Gly1-GEEEK ([⁎I]IB-Mal-d-GEEEK): a radioiodinated prosthetic group containing negatively charged d-glutamates for labeling internalizing monoclonal antibodies. Bioconjugate Chem. 2006;17:1085–1092
  43. Anderson CJ, Welch M. Radiometal-labeled agents (non-technetium) for diagnostic imaging. Chem Rev. 1999;99:2219–2234
  44. Franano FN, Edwards WB, Welch MJ, Duncan JR. Metabolism of receptor targeted 111In-DTPA-glycoproteins: identification of 111In-DTPA-epsilon-lysine as the primary metabolic and excretory product. Nucl Med Biol. 1994;21:1023–1034
  45. Rogers BE, Franano FN, Duncan JR, Edwards WB, Anderson CJ, Connett JM, et al. Identification of metabolites of 111In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo. Cancer Res. 1995;55(Suppl):5714s–5720s

☆ This work was supported by Grants NS20023 and CA42324 from the National Institutes of Health.

PII: S0969-8051(08)00240-0

doi: 10.1016/j.nucmedbio.2008.11.001

Nuclear Medicine and Biology
Volume 36, Issue 2 , Pages 117-128 , February 2009

Article Tools

* Image Usage & Resolution